This inventor holds 1 USPTO granted patent. Top assignee: Dong-A St Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Cheonhyoung Park: Innovator in Pharmaceutical Compounds
Introduction
Cheonhyoung Park is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as GCN2 inhibitors. His work is crucial for advancing treatments for diseases related to GCN2 activity.
Latest Patents
Cheonhyoung Park holds 1 patent for his innovative work titled "Compounds as GCN inhibitors, pharmaceutical compositions and uses thereof." This patent details novel compounds, specifically those of Formula (I), which act as GCN2 inhibitors. The pharmaceutical compositions he has developed include these compounds, which can inhibit GCN2 activity and are intended for treating or preventing related diseases.
Career Highlights
Park is associated with Dong-a ST Co., Ltd., a company known for its commitment to pharmaceutical advancements. His role at the company has allowed him to focus on research and development in the pharmaceutical sector, contributing to the creation of effective therapeutic solutions.
Collaborations
Throughout his career, Cheonhyoung Park has collaborated with esteemed colleagues, including Kimoon Ryu and Tae-hun Kim. These partnerships have fostered a collaborative environment that enhances innovation and research in their field.
Conclusion
Cheonhyoung Park's contributions to pharmaceutical innovations, particularly in GCN2 inhibitors, highlight his role as a key inventor in the industry. His work continues to pave the way for new treatments and advancements in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile